RU2016141621A - Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин - Google Patents
Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин Download PDFInfo
- Publication number
- RU2016141621A RU2016141621A RU2016141621A RU2016141621A RU2016141621A RU 2016141621 A RU2016141621 A RU 2016141621A RU 2016141621 A RU2016141621 A RU 2016141621A RU 2016141621 A RU2016141621 A RU 2016141621A RU 2016141621 A RU2016141621 A RU 2016141621A
- Authority
- RU
- Russia
- Prior art keywords
- aluminum
- immunogen
- adsorbed
- aluminum salt
- mpla
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16271—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969905P | 2014-03-25 | 2014-03-25 | |
| US61/969,905 | 2014-03-25 | ||
| PCT/US2014/045940 WO2015147899A1 (en) | 2014-03-25 | 2014-07-09 | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016141621A true RU2016141621A (ru) | 2018-04-25 |
| RU2016141621A3 RU2016141621A3 (enExample) | 2018-05-11 |
Family
ID=51302762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016141621A RU2016141621A (ru) | 2014-03-25 | 2014-07-09 | Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170165358A1 (enExample) |
| EP (1) | EP3122379A1 (enExample) |
| JP (1) | JP2017509713A (enExample) |
| KR (1) | KR20170016315A (enExample) |
| CN (1) | CN106535929A (enExample) |
| AU (1) | AU2014388299A1 (enExample) |
| BR (1) | BR112016021692A2 (enExample) |
| CA (1) | CA2943050A1 (enExample) |
| MX (1) | MX2016012166A (enExample) |
| RU (1) | RU2016141621A (enExample) |
| SG (2) | SG10201808312YA (enExample) |
| WO (1) | WO2015147899A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108135167B (zh) | 2015-08-19 | 2021-07-09 | 哈佛学院院长及董事 | 脂化psa组合物和方法 |
| WO2018014012A1 (en) * | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
| JP7385206B2 (ja) * | 2018-12-04 | 2023-11-22 | 国立大学法人大阪大学 | 免疫賦活剤 |
| AU2021311894B2 (en) | 2020-07-22 | 2025-02-27 | 3H Bio. Co., Ltd. | Peptide for immunotherapeutic agent |
| US12605443B2 (en) | 2020-10-13 | 2026-04-21 | The Government Of The United States, As Represented By The Secretary Of The Army | SAR-CoV-2 DNA vaccine and method of administering thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2156525A1 (en) * | 1993-02-19 | 1994-09-01 | Susan Dillon | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
| CN1124013A (zh) * | 1993-02-19 | 1996-06-05 | 史密丝克莱恩比彻姆公司 | 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物 |
| KR100310510B1 (ko) * | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| AU2006215419B2 (en) * | 2005-02-16 | 2012-03-08 | Novartis Vaccines And Diagnostics, Inc. | Adjuvant composition comprising aluminium phosphate and 3D-MPL |
| CN101678091A (zh) * | 2007-05-24 | 2010-03-24 | 葛兰素史密丝克莱恩生物有限公司 | 冷冻干燥的抗原组合物 |
| MX2012011189A (es) * | 2010-03-26 | 2013-02-07 | Glaxosmithkline Biolog Sa | Vacuna contra el virus e inmunodeficiencia humana. |
-
2014
- 2014-07-09 AU AU2014388299A patent/AU2014388299A1/en not_active Abandoned
- 2014-07-09 KR KR1020167025974A patent/KR20170016315A/ko not_active Withdrawn
- 2014-07-09 CN CN201480077507.5A patent/CN106535929A/zh active Pending
- 2014-07-09 MX MX2016012166A patent/MX2016012166A/es unknown
- 2014-07-09 RU RU2016141621A patent/RU2016141621A/ru not_active Application Discontinuation
- 2014-07-09 SG SG10201808312YA patent/SG10201808312YA/en unknown
- 2014-07-09 BR BR112016021692A patent/BR112016021692A2/pt not_active Application Discontinuation
- 2014-07-09 EP EP14750386.6A patent/EP3122379A1/en not_active Withdrawn
- 2014-07-09 WO PCT/US2014/045940 patent/WO2015147899A1/en not_active Ceased
- 2014-07-09 US US15/127,076 patent/US20170165358A1/en not_active Abandoned
- 2014-07-09 SG SG11201607404PA patent/SG11201607404PA/en unknown
- 2014-07-09 CA CA2943050A patent/CA2943050A1/en not_active Abandoned
- 2014-07-09 JP JP2017502571A patent/JP2017509713A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106535929A (zh) | 2017-03-22 |
| KR20170016315A (ko) | 2017-02-13 |
| EP3122379A1 (en) | 2017-02-01 |
| WO2015147899A1 (en) | 2015-10-01 |
| MX2016012166A (es) | 2017-03-15 |
| JP2017509713A (ja) | 2017-04-06 |
| RU2016141621A3 (enExample) | 2018-05-11 |
| AU2014388299A1 (en) | 2016-10-20 |
| SG10201808312YA (en) | 2018-10-30 |
| SG11201607404PA (en) | 2016-10-28 |
| US20170165358A1 (en) | 2017-06-15 |
| BR112016021692A2 (pt) | 2017-08-15 |
| CA2943050A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| HRP20160816T1 (hr) | Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica | |
| JP2011504486A5 (enExample) | ||
| FI3246044T4 (fi) | Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita | |
| RU2009144125A (ru) | Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе | |
| HRP20140488T1 (hr) | Cjepivo protiv influence | |
| JP2014532620A5 (enExample) | ||
| RU2014140521A (ru) | Адъювантные составы бустерных вакцин | |
| JP2006527762A5 (enExample) | ||
| JP2014506916A5 (enExample) | ||
| CA2400468A1 (en) | Proteosome influenza vaccine | |
| JP2016155867A5 (enExample) | ||
| RU2017145963A (ru) | Составы вакцин против неоплазии и способы их получения | |
| JP2015509522A5 (enExample) | ||
| JP2017014217A5 (enExample) | ||
| JP2018521028A5 (enExample) | ||
| RU2008119501A (ru) | Функциональные вирусоподоюные частицы гриппа (vlps) | |
| MY126588A (en) | Intranasal influenza virus vaccine | |
| RU2013114980A (ru) | Вакцинная композиция | |
| JP2021522296A5 (enExample) | ||
| RU2017129340A (ru) | Композиции nеisseria мeningitidis и способы их получения | |
| JP2012506421A5 (enExample) | ||
| RU2017137357A (ru) | Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал | |
| RU2015106745A (ru) | Иммуногенные композиции | |
| RU2015106930A (ru) | Комбинированные вакцины с менингококком серогруппы в и к/д/с |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20181008 |